Both polyclonal (Fli-1p) and monoclonal (Fli-1m) antibodies are available.
Among small round cell tumours, it is specific to Ewing sarcoma/PNET and lymphoblastic lymphoma:
|
29/411 |
||
0/321 |
|||
Neuroblastoma |
0/301 |
||
0/81 |
|||
7/81 |
|||
Estheioneuroblastoma |
0/81 |
||
1/11 |
|||
Mesenchymal chondrosarcoma |
0/11 |
||
The sensitivity and specificity of polyclonal (Fli-1p) and monoclonal (Fli-1m) anti-Fli-1, CD99 and FISH with the EWSR1 (22q12) dual-colour break-apart probe have been compared6. In normal tissues, Fli-1p expression was restricted to haemopoietic and endothelial cells. However, Fli-1m was also expressed by the prostate, breast , colon and squamous epithelium.
For each antibody, a threshold of 10% of tumour cells staining was set, cytoplasmic for CD99 and nuclear for Fli-1. |
||||
40/436 |
3/156 |
0.876 |
||
Fli-1m |
42/436 |
6/156 |
0.796 |
|
Fli-1p |
35/436 |
2/156 |
0.846 |
|
CD99+Fli-1m |
40/436 |
3/156 |
0.886 |
|
CD99+Fli-1p |
40/436 |
4/156 |
0.916 |
|
Fli-1m+Fli-1p |
42/436 |
6/156 |
0.896 |
|
CD99+Fli-1m+Fli-1p |
40/436 |
4/156 |
0.936 |
|
FISH |
19/386 |
0/156 |
|
|
In conclusion, Fli-1m is sensitive but lacks specificity for EWS/PNET. The combination of CD99 and Fli-1p is optimal.
endothelial cells and vascular tumours2:
Angiosarcoma | 20/222 | ||
Haemangioendothelioma |
11/122 | ||
Haemangioma, capillary |
7/72 | ||
Kaposi's sarcoma |
12/122 | ||
Melanoma |
0/72 | ||
Non-vascular sarcomas |
0/162 | ||
Carcinomas |
0/452 | ||
non-specific background cytoplasmic staining has been noted in breast epithelium and cutaneous eccrine glands.
Diagnostic utility
The identification of Ewing's sarcoma/PNET and its differentiation from other small round cell tumours, noting that lymphoblastic lymphoma is also positive for Fli-1.
The initial evidence is that Fli-1 may be superior in sensitivity 93% of vascular tumours tested (38 of 41) and specificity (100% to date for those tumours which are likely to form a differential diagnosis with vascular tumours) to CD31, CD34 and factor VIIIRA as a marker of vascular tumours. In particular, it looks promising for the differentiation of epithelioid angiosarcoma from carcinoma and epithelioid sarcoma.
References
This page last revised 20.1.2007.
©SMUHT/PW Bishop